J&J’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

The FDA has approved Johnson & Johnson’s nipocalimab (Imaavy) for adults and paediatric patients 12 years of age and older with generalized myasthenia gravis (gMG) and anti-acetylcholine ...

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

Earlier this year, nipocalimab data from Vivacity-MG3 supported the medication's long-term use in generalized myasthenia gravis when it is added to standard-of-care therapies. In particular ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Johnson & Johnson forecasts peak annual sales of over $5 billion for its FcRN blocker nipocalimab, which the US Food and Drug Administration recently approved and which the company acquired in its ...